New hope for HER2+ breast cancer: Real-World study tests daily pill pyrotinib

NCT ID NCT06495541

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 500 people with HER2-positive advanced breast cancer who are starting treatment with pyrotinib, a daily oral targeted therapy. Researchers want to see how well the drug controls the cancer and what side effects occur in everyday medical practice, not just in a strict clinical trial. The main goal is to measure how long the cancer stays under control before it progresses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pyrotinib (a targeted cancer drug taken as a daily pill)
What this could lead to: If successful, this could confirm pyrotinib as an effective first-line treatment for HER2-positive advanced breast cancer, potentially improving progression-free survival.
What could go wrong: This is an observational real-world study, not a randomized controlled trial, so results may be less definitive. Side effects of pyrotinib include diarrhea and other toxicities, and the drug may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER PYROTINIB RWS

More trials for these conditions

Other studies related to the condition(s) this trial covers.